In vitro activities of the newer quinolones garenoxacin, gatifloxacin, and gemifloxacin against human mycoplasmas.
The activities of garenoxacin, gatifloxacin, and gemifloxacin were compared with those of four fluoroquinolones against human mycoplasmas and ureaplasmas, including fluoroquinolone-resistant genetically characterized strains. Garenoxacin exhibited the highest activity, followed by gemifloxacin, moxifloxacin, and gatifloxacin. The minimal bactericidal activities of these three compounds were lower than those of the four fluoroquinolones.
Laboratoire de Bactériologie, Université Victor Segalen Bordeaux 2, 33076 Bordeaux, France.
S
S
Pereyre
H
H
Renaudin
C
C
Bébéar
C M
CM
Bébéar
D000890:Anti-Infective Agents / Q000494:pharmacology*; D024841:Fluoroquinolones / Q000494:pharmacology*; D000077734:Gatifloxacin; D000077735:Gemifloxacin; D006801:Humans; D008826:Microbial Sensitivity Tests; D009174:Mycoplasma / Q000187:drug effects*; D009175:Mycoplasma Infections / Q000382:microbiology; D009287:Naphthyridines / Q000494:pharmacology*; D015363:Quinolones / Q000494:pharmacology*
D000890:Anti-Infective Agents; D024841:Fluoroquinolones; D009287:Naphthyridines; D015363:Quinolones; D000077734:Gatifloxacin; D000077735:Gemifloxacin; C419689:garenoxacin